Miller Anestesia

61. Tegeder I, Lötsch J, Geisslinger G: Pharmacokinetics

of opioids in liver disease. Clin Pharmacokinet

37:17-40, 1999.

62. Haberer JP, Schoeffler P, Couderc E, et al: Fentanyl

pharmacokinetics in anaesthetized patients with

cirrhosis. Br J Anaesth 54:1267-1270, 1982.

63. Chauvin M, Ferrier C, Haberer JP, et al: Sufentanil

pharmacokinetics in patients with cirrhosis. Anesth

Analg 68:1-4, 1989.

64. Ferrier C, Marty J, Bouffard Y, et al: Alfentanil phar-

macokinetics in patients with cirrhosis. Anesthesio-

logy 62:480-484, 1985.

65. Raucoules-Aimé M, Kaidomar M, Levron JC, et al:

Hepatic disposition of alfentanil and sufentanil in

patients undergoing orthotopic liver transplanta-

tion. Anesth Analg 84:1019-1024, 1997.

66. Navapurkar VU, Archer S, Gupta SK, et al: Metabo-

lism of remifentanil during liver transplantation. Br

J Anaesth 81:881-886, 1998.

67. Dumont L, Picard V, Marti RA, et al: Use of remi-

fentanil in a patient with chronic hepatic failure. Br

J Anaesth 81:265-267, 1998.

68. Dershwitz M, Hoke JF, Rosow CE, et al: Pharmaco-

kinetics and pharmacodynamics of remifentanil in

volunteer subjects with severe liver disease. Anes-

thesiology 84:812-820, 1996.

69. Pandele G, Chaux F, Salvadori C, et al: Thiopental

pharmacokinetics in patients with cirrhosis. Anes-

thesiology 59:123-126, 1983.

70. Couderc E, Ferrier C, Harberer JP, et al: Thiopen-

tone pharmacokinetics in patients with chronic

alcoholism. Br J Anaesth 56:1393-1396, 1984.

71. Duvaldestin P, Chauvin M, Lebrault C, et al: Effect

of upper abdominal surgery and cirrhosis upon the

pharmacokinetics of methohexital. Acta Anaesthe-

siol Scand 35:159-163, 1991.

72. Van Beem H, Manger FW, Van Boxtel C, et al: Eto-

midate anaesthesia in patients with cirrhosis of the

liver: Pharmacokinetic data. Anaesthesia 38:61-62,

1983.

73. Servin F, Desmonts JM, Haberer JP, et al: Pharma-

cokinetics and protein binding of propofol in

patients with cirrhosis. Anesthesiology 69:887-891,

1988.

74. Servin F, Cockshott ID, Farinotti R, et al: Pharma-

cokinetics of propofol infusions in patients with

cirrhosis. Br J Anaesth 65:177-183, 1990.

75. MacGilchrist AJ, Birnie GG, Cook A, et al: Pharma-

cokinetics and pharmacodynamics of intravenous

midazolam in patients with severe alcoholic cirrho-

sis. Gut 27:190-195, 1986.

76. Trouvin JH, Farinotti R, Haberer JP, et al: Pharma-

cokinetics of midazolam in anaesthetized cirrhotic

patients. Br J Anaesth 60:762-767, 1988.

77. Baughman VL, Cunningham FE, Layden T. Phar-

macokinetic/pharmacodynamic effects of dexme-

detomidine in patients with hepatic failure. Anesth

Analg 90(Suppl):S391, 2000.

78. De Wolf AM, Fragen RJ, Avram MJ, et al: The phar-

macokinetics of dexmedetomidine in volunteers

with severe renal impairment. Anesth Analg

93:1205-1209, 2001.

79. Venn RM, Karol MD, Grounds RM: Pharmacokine-

tics of dexmedetomidine infusions for sedation of

postoperative patients requiring intensive care. Br J

Anaesth 88:669-675, 2002.

80. Upton RA, Nguyen TL, Miller RD, et al: Renal and

biliary elimination of vecuronium (ORG NC 45) and

pancuronium in rats. Anesth Analg 61:313-316, 1982.

81. Bencini AF, Scaf AH, Sohn YJ, et al: Hepatobiliary

disposition of vecuronium bromide in man. Br J

Anaesth 58:988-995, 1986.

82. Hunter JM, Parker CJ, Bell CF: The use of different

doses of vecuronium in patients with liver dys-

function. Br J Anaesth 57:758-764, 1985.

83. Lebrault C, Berger JL, D’Hollander AA, et al: Phar-

macokinetics and pharmacodynamics of vecuro-

nium (ORG NC 45) in patients with cirrhosis.

Anesthesiology 62:601-605, 1985.

84. Arden JR, Lynam DP, Castagnoli KP, et al: Vecuro-

nium in alcoholic liver disease: A pharmacokinetic

and pharmacodynamic analysis. Anesthesiology

68:771-776, 1988.

85. Magorian T, Wood P, Caldwell J, et al: The pharma-

cokinetics and neuromuscular effects of rocuro-

nium bromide in patients with liver disease. Anesth

Analg 80:754-759, 1995.

86. Khalil M, D’Honneur G, Duvaldestin P, et al: Phar-

macokinetics and pharmacodynamics of rocuro-

nium in patients with cirrhosis. Anesthesiology

80:1241-1247, 1994.

87. Gao L, Ramzan I, Baker B: Rocuronium infusion

requirements and plasma concentrations at cons-

tant levels of neuromuscular paralysis during three

phases of liver transplantation. J Clin Anesth

15:257-266, 2003.

88. Duvaldestin P, Agoston S, Henzel D, et al: Pancuro-

nium pharmacokinetics in patients with liver cirr-

hosis. Br J Anaesth 50:1131-1136, 1978.

89. De Wolf AM, Freeman JA, Scott VL, et al: Pharma-

cokinetics and pharmacodynamics of cisatracu-

rium in patients with end-stage liver disease

undergoing liver transplantation. Br J Anaesth

76:624-628, 1996.

90. Ward S, Neill EA: Pharmacokinetics of atracurium

in acute hepatic failure (with acute renal failure). Br

J Anaesth 55:1169-1172, 1983.

91. Kisor DF, Schmith VD: Clinical pharmacokinetics

of cisatracurium besylate. Clin Pharmacokinet

36:27-40, 1999.

92. Cammu G, Bossuyt G, De Baerdemaeker L, et al:

Dose requirements and recovery profile of an infu-

sion of cisatracurium during liver transplantation. J

Clin Anesth 14:135-139, 2002.

93. Fodale V, Santamaria LB: Laudanosine, an atracu-

rium and cisatracuriummetabolite. Eur J Anaesthe-

siol 19:466-473, 2002.

94. Cook DR, Freeman JA, Lai AA, et al: Pharmacoki-

netics of mivacurium in normal patients and in

those with hepatic or renal failure. Br J Anaesth

69:580-585, 1992.

95. Devlin JC, Head-Rapson AG, Parker CJ: Pharmaco-

dynamics of mivacurium chloride in patients with

hepatic cirrhosis. Br J Anaesth 71:227-231, 1993.

96. Head-Rapson AG, Devlin JC, Parker JC: Pharmaco-

kinetics of the three isomers of mivacurium and

pharmacodynamics of the chiral mixture in hepatic

cirrhosis. Br J Anaesth 73:613-618, 1994.

97. Thomas SD, Boyd AH: Prolonged neuromuscular

block associated with acute fatty liver of pregnancy

and reduced plasma cholinesterase. Eur J Anaesthe-

siol 11:245-249, 1994.

98. Eagle KA, Berger PB, Calkins H, et al: ACC/AHA

Guideline Update for Perioperative Cardiovascular

Evaluation for Noncardiac Surgery—Executive

Summary. A report of the American College of Car-

diology/American Heart Association Task Force on

Practice Guidelines (Committee to Update the 1996

Guidelines on Perioperative Evaluation for noncar-

diac Surgery). Anesth Analg 94:1052-1064, 2002.

99. Rothenberg DM: Postoperative renal dysfunction.

Afifi S, Rosenbaum S (eds): Problems in Anesthe-

sia: PACU and Anesthetic Management. Philadel-

phia, Lippincott-Williams & Wilkins, 2000, pp

314-325.

100. Kamath PS: Clinical approach to the patient with

abnormal liver test results. Mayo Clin Proc 71:1089-

1095, 1996.

101. Bates B, Yelling JA: The yield of multiphasic scree-

ning. JAMA 222:74-78, 1972.

102. Farrell RL, DeColli JA, Chappelka AR: Significance

of abnormal liver function studies in psychiatric

admissions to military hospitals. Mil Med 140:101-

103, 1975.

103. Pratt DS, Kaplan MM: Primary care: Evaluation of

abnormal liver-enzyme results in asymptomatic

patients. N Engl J Med 342:1266-1271, 2000.

104. Cohn JA, Kaplan MM: The SGOT/SGPT ratio—an

indicator of alcoholic liver disease. Dig Dis Sci

24:835-838, 1979.

105. Powell-Jackson P, Greenway B, Williams R: Adverse

effects of exploratory laparotomy in patients with

unsuspected liver disease. Br J Surg 69:449-451, 1982.

106. Greenwood SM, Leffler CT, Minkowitz S: The

increased mortality of open liver biopsy in alcoholic

hepatitis. Surg Gynecol Obstet 134:600-604, 1972.

107. Bell RH Jr, Miyai K, Orloff MJ: Outcome in cirrhotic

patients with acute alcoholic hepatitis after emer-

gency portocaval shunt for bleeding esophageal

varices. Am J Surg 147:78-84, 1984.

108. Hay JE, Czaja AJ, Rakela J, Ludwig J: The nature of

unexplained chronic aminotransferase elevations of

amild tomoderate degree in asymptomatic patients.

Hepatology 9:193-197, 1989.

109. Hultcrantz R, Glauman H, Lindberg G, Nilsson LHS:

Liver investigation in 149 asymptomatic patients with

moderately elevated activities of serum aminotrans-

ferases. Scand J Gastroenterol 21:109-113, 1986.

110. Behrns KE: Hepatic steatosis as a potential risk

factor for major hepatic resection. J Gastrointest

Surg 2:292-298, 1998.

111. Brolin RE, Bradley LJ, Rajiv V, Taliwal V: Unsuspec-

ted cirrhosis discovered during elective obesity

operations. Arch Surg 133:84-88, 1998.

112. Friedman LS: The risk of surgery in patients with

liver disease. Hepatology 29:1617-1623, 1999.

113. Runyon BA: Surgical procedures are well tolerated

by patients with asymptomatic chronic hepatitis. J

Clin Gastroenterol 8:542-544, 1986.

114. Higashi H, Matsumata T, Adachi E, et al: Influence

of viral hepatitis status on operative morbidity and

mortality in patients with primary hepatocellular

carcinoma. Br J Surg 81:1342-1345, 1994.

115. Ko S, Nakajima Y, Kanehiro H, et al: Significant

influence of accompanying chronic hepatitis status

on recurrence of hepatocellular carcinoma after

hepatectomy: Result of multivariate analysis. Ann

Surg 224:591-595, 1996.

116. Pugh RNH, Murray-Lyon IM, Dawson JL, et al:

Transection of oesophagus for bleeding of oesopha-

geal varices. Br J Surg 60:646-649, 1973.

117. Garrison RN, Cryer HM, Howard DA, Polk HC Jr:

Clarification of factors for abdominal operations in

patients with hepatic cirrhosis. Ann Surg 199:648-

655, 1984.

118. Mansour A, Watson W, Shayani V, Pickelman J:

Abdominal operations in patients with cirrhosis:

Still a major surgical challenge. Surgery 22:730-736,

1997.

119. Bloch RS, Allaben RD, Walt AJ: Cholecystectomy in

patients with cirrhosis. Arch Surg 120:669-672,

1985.

120. Metcalf AMT, Dozois RR, Wolff BG, Beart RW Jr:

The surgical risk of colectomy in patients with cirr-

hosis. Dis Colon Rectum 30:529-531, 1987.

121. Lehnert T, Herfarth C: Peptic ulcer surgery in

patients with liver cirrhosis. Ann Surg 217:338-346,

1993.

122. Wong R, Rappaport W, Witte C, et al: Risk of nons-

hunt abdominal operation in the patient with cirr-

hosis. J Am Coll Surg 179:412-416, 1994.

123. Rice RE, O’Keefe GE, Helton WS, Johansen K:

Morbid prognostic features in patients with chronic

liver failure undergoing nonhepatic surgery. Arch

Surg 132:880-885, 1997.

124. Ziser A, Plevak DJ, Wiesner RH, et al: Morbidity and

mortality in cirrhotic patients undergoing anesthe-

sia and surgery. Anesthesiology 90:42-53, 1999.

125. Olthoff KM, Brown RS Jr, Delmonico FL, et al:

Summary report of a national conference: evolving

concepts in liver allocation in the MELD and PELD

era: December 8, 2003, Washington, DC, USA. Liver

Transplant 10(10 Suppl. 2):A6-22, 2004.

126. Kamath PS, Wiesner RH, Malinchoc M, et al: A

model to predict survival in patients with end-stage

liver disease. Hepatology 33:464-470, 2001.

127. Said A, Willliams J, Holden J, et al: Model for end-

stage liver disease score predicts mortality across a

broad spectrum of liver disease. J Hepatol 40:897-

903, 2004.

128. Dunn W, Jamil LH, Brown LS, et al: MELD accura-

tely predicts mortality in patients with alcoholic

hepatitis. Hepatology 41:353-358, 2005.

129. Huo Tl, Wu JC, Lin HC, et al: Evaluation of the

increase in model for end-stage liver disease

(

∆

MELD) score over time as a prognostic predictor

in patients with advanced cirrhosis: Risk factor analy-

sis and comparison with initial MELD and Child-

Turcotte-Pugh score. J Hepatol 42:826-832, 2005.

Anestesia y el sistema hepatobiliar

1917

Sección IV

Anestesia por subespecialidades en el adulto